VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
WRBW. R. Berkley Corporation
$71.27$26.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksWRBFinancials

W. R. Berkley Corporation (WRB) Financials

30Y historyFree accessUpdated daily

Underwriting efficiency remains superior with a 83.3% combined ratio in 2026Q1, though revenue growth has moderated to 4.0% from the double-digit levels seen throughout 2024.

WRB Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue14.85B14.71B13.64B12.14B11.17B9.46B8.1B7.9B7.69B8.01B7.65B7.21B7.54B6.41B5.82B4.91B4.51B4.43B4.71B5.59B5.39B5B4.51B3.63B2.57B1.94B1.78B1.67B1.58B1.4B1.23B
Revenue Growth %6.59%7.82%12.32%8.74%18.1%16.75%2.49%2.74%-3.99%4.66%6.21%-4.41%17.64%10.05%18.63%8.91%1.72%-5.9%-15.74%3.59%7.96%10.74%24.3%41.46%32.15%9.01%6.43%5.76%13.01%14.29%19.89%
Medical Costs & Claims10.97B11.79B10.52B9.42B8.73B7.43B6.75B6.42B6.31B6.36B6.21B5.92B5.49B4.28B3.95B3.52B3.09B2.34B2.69B3.11B3.15B3.02B2.76B2.96B1.46B1.38B1.09B1.09B914.76M734.42M669.16M
Medical Cost Ratio %73.86%80.19%77.11%77.56%78.17%78.61%83.36%81.29%82.04%79.43%81.17%82.1%72.82%66.74%67.85%71.68%68.57%52.73%57.1%55.61%58.46%60.52%61.27%81.42%57.05%71.09%61.44%64.88%57.8%52.45%54.62%
Gross Profit3.88B2.91B3.12B2.72B2.44B2.02B1.35B1.48B1.38B1.65B1.44B1.29B2.05B2.13B1.87B1.39B1.42B2.09B2.02B2.48B2.24B1.97B1.75B674.58M1.1B561.3M686.88M587.84M667.75M665.88M556.01M
Gross Margin %26.14%19.81%22.89%22.44%21.83%21.39%16.64%18.71%17.96%20.57%18.83%17.9%27.18%33.26%32.15%28.32%31.43%47.27%42.9%44.39%41.54%39.48%38.73%18.58%42.95%28.91%38.56%35.12%42.2%47.55%45.38%
Gross Profit Growth %--6.66%14.58%11.75%20.53%50.08%-8.82%7.01%-16.18%14.34%11.74%-37.05%-3.88%13.85%34.67%-1.85%-32.36%3.68%-18.56%10.69%13.62%12.87%159.06%-38.79%96.35%-18.28%16.85%-11.97%0.28%19.76%23.3%
Operating Expenses1.47B579.43M857.12M969.99M718.33M739.87M642.96M625.23M569.26M875.24M544.93M557.93M1.1B1.43B1.17B877.39M817.76M1.71B1.69B1.39B1.25B1.2B1.11B185.28M842.68M712.69M646.02M667.09M604.97M-685.52M440.96M
OpEx / Revenue %9.9%3.94%6.28%7.99%6.43%7.82%7.94%7.91%7.4%10.93%7.12%7.74%14.55%22.36%20.1%17.87%18.14%38.64%35.97%24.84%23.22%24.06%24.58%5.1%32.84%36.7%36.27%39.86%38.23%-48.96%35.99%
Depreciation & Amortization-38.5M-32.82M-170.64M-20.86M55.87M129.68M135.06M113.39M131.11M112.96M86.05M85.14M88.84M103.09M103.42M88.01M82.87M78.88M83.95M73.7M65.67M63.05M54.83M20.32M17.94M17.49M21.7M23.6M22.66M11.9M8.59M
Combined Ratio %83.76%84.13%83.4%85.55%84.6%86.43%91.3%89.21%89.44%90.35%88.29%89.84%87.37%89.09%87.95%89.55%86.71%91.37%93.07%80.45%81.67%84.58%85.85%86.52%89.89%107.8%97.71%104.73%96.03%3.49%90.61%
Operating Income2.41B2.33B2.26B1.75B1.72B1.28B704.8M852.92M812.09M772.77M896.44M732.03M952.2M698.89M701.93M513.09M598.91M382.23M326.32M1.09B988.64M770.54M638.51M489.3M259.43M-151.39M40.85M-79.25M62.78M1.35B115.05M
Operating Margin %16.24%15.87%16.6%14.45%15.4%13.57%8.7%10.79%10.56%9.65%11.71%10.16%12.63%10.91%12.05%10.45%13.29%8.63%6.93%19.55%18.33%15.42%14.15%13.48%10.11%-7.8%2.29%-4.73%3.97%96.51%9.39%
Operating Income Growth %-3.08%29.07%2.02%34.05%82.02%-17.37%5.03%5.09%-13.8%22.46%-23.12%36.24%-0.43%36.81%-14.33%56.69%17.13%-70.13%10.49%28.31%20.68%30.49%88.61%271.36%-470.6%151.55%-226.23%-95.35%1074.63%39.04%
EBITDA2.37B2.3B2.09B1.73B1.78B1.41B839.87M966.31M943.2M885.73M982.49M817.17M1.04B801.98M805.35M601.1M681.78M461.11M410.27M1.17B1.05B833.59M693.34M509.63M277.38M-133.9M62.55M-55.65M85.44M1.36B123.64M
EBITDA Margin %15.95%15.65%15.35%14.28%15.9%14.94%10.37%12.23%12.26%11.06%12.84%11.34%13.81%12.51%13.83%12.24%15.13%10.41%8.71%20.87%19.54%16.68%15.37%14.04%10.81%-6.9%3.51%-3.33%5.4%97.36%10.09%
Interest Expense126.87M126.89M126.91M127.46M130.37M147.18M150.54M153.41M157.19M147.3M140.9M130.95M128.17M123.18M126.3M112.51M106.97M87.99M84.62M89M92.52M85.93M66.42M54.73M45.48M45.72M47.6M50.8M48.82M48.87M31.96M
Non-Operating Income-70.72M-70.74M-126.91M-127.46M-130.37M-147.18M-150.54M-153.41M-157.19M-147.3M-140.9M-130.95M-128.17M-123.18M-126.3M-112.51M-106.97M-87.99M-84.62M-89M-92.52M-85.93M-66.42M-54.73M-45.48M-45.72M-47.6M-50.8M-48.82M1.3B-31.96M
Pretax Income2.36B2.28B2.26B1.75B1.72B1.28B704.8M852.92M812.09M772.77M896.44M732.03M952.2M698.89M701.93M513.09M598.91M382.23M326.32M1.09B988.64M770.54M638.51M489.3M259.43M-151.39M40.85M-79.25M62.78M129.7M115.05M
Pretax Margin %15.88%15.51%16.6%14.45%15.4%13.57%8.7%10.79%10.56%9.65%11.71%10.16%12.63%10.91%12.05%10.45%13.29%8.63%6.93%19.55%18.33%15.42%14.15%13.48%10.11%-7.8%2.29%-4.73%3.97%9.26%9.39%
Income Tax475.03M495.77M509.92M370.56M334.73M251.89M171.82M168.94M163.03M219.43M292.95M227.92M302.59M193.59M191.28M121.94M152.23M73.15M44.92M323.07M286.4M222.52M196.24M150.63M84.14M-56.66M2.45M-45.77M5.46M30.7M25.1M
Effective Tax Rate %20.15%21.74%22.52%21.12%19.46%19.63%24.38%19.81%20.08%28.4%32.68%31.14%31.78%27.7%27.25%23.77%25.42%19.14%13.77%29.57%28.97%28.88%30.73%30.78%32.43%37.43%6%57.75%8.7%23.67%21.82%
Net Income1.88B1.78B1.76B1.38B1.38B1.02B530.67M681.94M640.75M549.09M601.92M503.69M648.88M499.93M510.59M391.21M446.4M309.06M281.14M766.24M699.52M544.89M438.11M337.22M175.04M-91.55M34.08M-36.6M58.76M99M90.26M
Net Margin %12.64%12.1%12.88%11.38%12.37%10.81%6.55%8.63%8.33%6.85%7.86%6.99%8.61%7.8%8.77%7.97%9.9%6.97%5.97%13.71%12.97%10.9%9.71%9.29%6.82%-4.71%1.91%-2.19%3.71%7.07%7.37%
Net Income Growth %8.42%1.33%27.13%0.02%35.07%92.68%-22.18%6.43%16.69%-8.78%19.5%-22.38%29.8%-2.09%30.52%-12.36%44.44%9.93%-63.31%9.54%28.38%24.37%29.92%92.65%291.21%-368.65%193.1%-162.29%-40.65%9.68%48.26%
EPS (Diluted)4.754.454.363.373.292.441.251.561.481.261.391.151.441.051.581.201.280.830.721.731.541.210.980.760.44-0.270.12-0.120.140.270.22
EPS Growth %9.51%2.06%29.38%2.43%34.84%95.2%-19.87%5.41%17.46%-9.35%20.87%-20.14%37.14%-33.54%31.67%-6.25%54.22%15.28%-58.38%12.34%27.27%23.47%28.95%72.73%262.96%-325%200%-185.71%-48.15%22.73%29.41%
EPS (Basic)-4.484.393.403.332.461.261.591.481.301.451.201.501.091.651.261.330.860.751.801.621.271.030.800.45-0.270.12-0.120.140.270.22
Diluted Shares Outstanding394.78M399.13M403.22M409.95M419.19M419.62M424.72M435.42M432.89M435.44M433.87M439.39M451.08M475.01M322.46M327.76M348.93M374.79M390.27M442.57M454.89M450.74M446.03M441.13M400.98M333.42M296.96M295.2M330.94M343.29M339.73M

Key Metrics

Growth RegimeMixed
ProfitabilityStrong
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Social inflation litigation exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Normalizing Amid Competition

As indicated by the most recent quarterly data, W. R. Berkley's revenue growth has decelerated to 4.0% in 2026Q1, a notable shift from the double-digit expansion observed throughout 2024, suggesting that the company is encountering a more challenging pricing environment across its specialized commercial insurance segments.

The deceleration in top-line growth may reflect a strategic pivot toward underwriting discipline rather than volume expansion in a softening market. Investors should monitor whether this trend indicates a broader industry-wide pricing fatigue or a deliberate choice by management to prioritize margin protection over market share.

Underwriting Profitability Remains Highly Resilient

Based on the reported combined ratio of 83.3% for 2026Q1, W. R. Berkley continues to demonstrate superior underwriting efficiency, maintaining a consistent profit margin that significantly outperforms the industry threshold of 100% despite the inherent volatility of its specialized casualty and professional liability insurance portfolios.

The company's ability to keep the combined ratio well below the break-even point suggests that its decentralized boutique unit structure effectively manages risk selection. This performance appears to validate the firm's focus on niche markets where granular underwriting expertise can command higher premiums relative to the underlying loss costs.

Loss Ratio Volatility Warrants Scrutiny

According to the provided financial statements, the loss ratio experienced a sharp spike to 79.4% in 2025Q4 before moderating to 52.5% in 2026Q1, highlighting potential instability in claim estimation that may necessitate a closer examination of the company's prior-year reserve development and long-tail liability adequacy.

The significant variance in the loss ratio suggests that the company may be navigating unpredictable claim patterns, possibly linked to the broader industry trend of social inflation. Analysts should investigate whether the recent improvement in 2026Q1 is a sustainable trend or merely a temporary fluctuation resulting from favorable reserve releases.

Litigation Tailwinds Threaten Earnings Quality

While W. R. Berkley reports strong operating income, the persistent threat of social inflation and nuclear jury verdicts, as noted in recent industry context, may imply that current underwriting profits are potentially masking future reserve strengthening requirements that could weigh on long-term earnings sustainability for the firm.

The reliance on decentralized units, while agile, may create challenges in maintaining uniform reserve standards across diverse specialty lines. Investors should remain cautious, as any systemic underestimation of long-tail casualty claims could lead to significant earnings volatility if management is forced to adjust reserves in future periods.

WRB — Frequently Asked Questions

Quick answers to the most common questions about buying WRB stock.

What was W. R. Berkley Corporation's (WRB) revenue in 2025?

For fiscal year 2025, W. R. Berkley Corporation (WRB) reported total revenue of $14.71B. This represents a 1100.3% increase compared to $1.23B in 1996.

Is W. R. Berkley Corporation (WRB) profitable?

W. R. Berkley Corporation (WRB) is profitable, generating $1.78B in net income for the fiscal year ending 2025 with a net profit margin of 12.1%.

What is W. R. Berkley Corporation's operating profit margin?

W. R. Berkley Corporation (WRB) reported an operating income of $2.33B, resulting in an operating profit margin of 15.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is W. R. Berkley Corporation's gross profit and gross margin?

W. R. Berkley Corporation (WRB) generated $2.91B in gross profit for the year, representing a gross profit margin of 19.8%. This demonstrates the company's core pricing power and production efficiency.